EUROMEDICA  Hanover 6-7  Juni 2008	Advanced methods of diagnosis, treatment and prophylactics
	European Academy of Natural Sciences, Hanover European Scientific Society, Hanover Russian Academy of Natural Sciences, Moscow

Home

Abstracts

Contact

Disclaimer

Actuality. The problem of the spread of oncopathology is very actual. WHO specialists think that in 2009 cases of cancer diseases comes to apprx. 12 mln., with lethal prognosis of about 7 mln. Also, specialists forecast an increase of cancer diseases and deaths by 1 %, however in 2010 oncopathology will be the first disease after heart-vascular diseases. According to American specialists, in 2010 cancer will be a leading reason of death in the world, exceeding heart diseases, HIV, malaria and TB. Also cancer is moving now from developing countries to developed countries. According to WHO expert’s conclusion, in 2030 the amount of cancer deaths might double and WHO doctors call up to undertake measures against that problem. One of the grounds for quick spread of that pathology is lack of its early diagnosis and dispensary networks. Specialists noticed that the tumor diagnostics at 1-2 stages of its development significantly improves therapy results. Namely, in acute lymphoblastic leukemia - up to 80%, lymphogranulomatosis -up to 95%, lymphomas - up to 65% and more, adenomyosarcoma - 90%. In this connection one of the perspective directions against cancer is conduction of laboratory tests, which allows detecting the incidence of malignant tumor in the body.

Objects. 457 patients with oncopathology of different localization underwent a serum research by V. Vladimirov method – “Oncotest-2”. The control group comprised 37 almost healthy patients.

Method. Method “Oncotest-2” (Patent Nr. 77549, 15.12.2006, Ukraine; Patent LV13577 28.08.2007, Latvia) is based on biochemical identification of calcium-protein complex (CPC), which level raises at the first signs of cell malignization. Lately “oncotest-2” has been introduced at Kiev Surgery and Rehabilitation Center for Pathology of Thyroid gland; Ukrainian Neurosurgery Institute; Kiev State Cancer Hospital; Central Immunological Institute (Russian Federation, Moscow); National Institute of Clinical Research (USA, California). According to the hypothesis the tumor antigens (AG) settle on top of red blood cells, while content of ion-calcium in their structures is common for both, the AG are the same as CPC. The test gives opportunity to detect tumor at an early stage of its incidence, which means at the stage where tumor volume is not higher than 10(4)-10(5) cells.

Results. The obtained results detect a high sensitivity of the test (75-93%) of the cases and specify in 8094% of the cases. According to the combined results with the author the diagnostic sensitivity of the test in Ca gl. Mammae is 96.2%, Ca prostate – 80%, Ca ventriculi – 96-98%. Among almost healthy people with cancer in family registries, the test was positive in 4 patients. In 3 of them chronic prostatitis was detected and one case of mastopathy. Further medical examination confirmed Ca prostate and Ca gl. Mammae. The shortcomings of test: the research does not allow finding tumor localization, supplemental research methods of cancer diagnostic are needed. The results of offered screening programs of groups with increased oncology risk and “Oncotest2” method enables to increase the oncology detection in 1.3 times, which is more effective than conventional diagnostic methods. Preliminary calculation showed that Screening Program of early diagnosis and prevention of oncology with the use “Oncotest-2” allows preventing untimely death in 30-40% cases. Groups with higher oncology risk reveal 2.5 times more cases of diffuse carcinoma of stomach and colon cancer; more than in 4 times – metroscirrhus, ovarian cancer, breast cancer and in 4 times carcinoma of lung. This data gives ground to reasonable and systematical examination of higher risk groups.

Conclusions. “Oncotest-2” is recommended to use in patients with oncological risk to detect cancer on early stages and also for differential diagnostic of benign and malignant tumors. Thus, the solution of the problem of accelerated spread of oncopathology should be found in complex: aiming not only on developing new effective therapies, but focusing on introduction of Screening-Program for early diagnosis, which leads to more effective clinical outcome.